Abstract: Monitoring system and method for identifying object of interest after the object of interest has undergone a change in appearance. The method includes detecting an appearance of a first object of interest in a first zone and determining whether the first object of interest has appeared in a second zone adjacent the first zone within a predetermined time. When the first object of interest has not appeared in the second zone within the predetermined time, the method includes adding the first object of interest to a disappearance database and detecting an unexplained appearance of a second object of interest in a third zone of the plurality of zones. When an unexplained appearance of the second object of interest is detected, the method includes adding the second object of interest to a suspect database, and generating a notification for a first responder regarding the second object of interest.

Abstract: Monitoring system and method for identifying object of interest after the object of interest has undergone a change in appearance. The method includes detecting an appearance of a first object of interest in a first zone and determining whether the first object of interest has appeared in a second zone adjacent the first zone within a predetermined time. When the first object of interest has not appeared in the second zone within the predetermined time, the method includes adding the first object of interest to a disappearance database and detecting an unexplained appearance of a second object of interest in a third zone of the plurality of zones. When an unexplained appearance of the second object of interest is detected, the method includes adding the second object of interest to a suspect database, and generating a notification for a first responder regarding the second object of interest.

Abstract: A method of cell-based therapy for treating an autoimmune disease is disclosed. The method is directed at stimulating leukocytes and/or dendritic cells to interrupt autoimmunity in a host. The method provides a Fc? receptor-specific complex or a complex which results in the co-crosslinking of Fc?-chains for treating the leukocytes and/or dendritic cells which are in turn used to elicit an autoimmune interruption response in a subject with an autoimmune disease. The Fc? receptor-specific complex and/or complex which results in the co-crosslinking of Fc?-chains is used to treat a biological sample comprising leukocytes and/or dendritic cells from a patient, and upon reintroducing said biological sample to the patient, the pre-treated dendritic cells illicit an autoimmune interruption response in vivo.

Abstract: A method for treating autoimmune diseases in a mammal which method comprises administering to the mammal an effective amount of at least one antibody specific for a soluble antigen is provided. Furthermore, a novel mechanism of action has been established in accordance with the present invention for antibody-based treatment regimes for autoimmune disease, including but not limited to anti-CD44 and soluble antigen specific antibody treatment regimes.

Abstract: A method of cell-based therapy for treating an autoimmune disease is disclosed. The method is directed at stimulating leukocytes and/or dendritic cells to interrupt autoimmunity in a host. The method provides a Fc? receptor-specific complex or a complex which results in the co-crosslinking of Fc?-chains for treating the leukocytes and/or dendritic cells which are in turn used to elicit an autoimmune interruption response in a subject with an autoimmune disease. The Fc? receptor-specific complex and/or complex which results in the co-crosslinking of Fc?-chains is used to treat a biological sample comprising leukocytes and/or dendritic cells from a patient, and upon reintroducing said biological sample to the patient, the pre-treated dendritic cells illicit an autoimmune interruption response in vivo.

Abstract: The present invention relates to a method and composition utilizing monoclonal intravenous immunoglobulin (mIVIG) for increasing platelet cell counts in thrombocytopenia. The method and composition are suitable for treatments of patients suffering from medical conditions, such as idiopathlic thrombocytopenic purpura (ITP), which result in low platelet cell numbers.